HCPCS Level II
Q5134
Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg
Codes near Q5134
These sit next to Q5134 in the CMS Level II file. All Q codes
- Q5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
- Q5130Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
- Q5131Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
- Q5132Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
- Q5133Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
- Q5135Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
- Q5136Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg
- Q5137Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg
- Q5138Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg
- Q5139Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 61314-0543-94 | Tyruko | Sandoz Inc. | 300 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.